The pharma DTC content production layer is being eaten by AI on a 12-month horizon. Independent agencies that move first — license the OVYN engine (Intelligence + Content Engine + Activation), white-label, keep client relationships — keep their scope. Agencies that wait, lose it. This is the conversation we should be having.
Pharma DTC content production — variant adaptation, MLR prep, channel formatting, performance reporting — is the agency layer most exposed to AI displacement on a 12-month horizon. We built the engine that does it. Your move is to license it under your brand, keep client relationships, and let your strategy team focus on the work that's actually defensible: positioning, brand voice, account leadership.
Per-seat license starting at $24K per seat per year, with a 3-seat minimum (so $72K minimum annual). On top: revenue share on pharma deals you close — 30% of first-year ACV, 20% in years 2–3, 15% lifetime thereafter. We're flexible on structure — flat license vs revenue-share weighted is a conversation.
2 weeks for a full reskin: your brand colors, fonts, domain, lockup, favicon, OG image. 4–6 weeks for a full embed into your existing client portal if that's the goal. We've architected for white-label from day one — the entire palette is in a single config file.
Per-client exclusive: yes. If you bring us a pharma client, we don't take a parallel direct engagement with that client during your contract term. Globally non-exclusive across categories — multiple agencies can license simultaneously. We do prefer one deeply-embedded media-agency partner per biotech-vertical though, so let us know early.
Standard agency-side language in the contract: any deal sourced through your relationships pays you the revenue share regardless of how the contract is structured. We don't end-run partners. If a client insists on direct, we negotiate a transition or step-down.
Yes, but they're trained, not expected to figure it out. 2-week onboarding workshop with your strategy + AD team. After that, the team operates the engine for your clients exactly the same way they'd run a creative brief through your existing process — just faster.
We integrate underneath your existing scope. Your SOW with the client doesn't change. Your account team uses the engine on the production layer; from the client's view, you've just gotten faster + more variant-rich. The internal cost change is yours to manage.
You buy paid media for biotech clients. We integrate at the file-handoff point — MLR-approved creative flows from us into your portal, performance flows back via API into our dashboard. Your client sees one unified view.
You've sat on the brand side. You know which deals are real, which procurement teams move fast, which biotechs are AI-curious right now. You bring warm intros; we close + deliver.
You sell into pharma marketing in an adjacent category — analytics, MLR workflow, audience data, asset management. We integrate so customers see seamless value across both stacks. No redundancy, no overlap.